University of Virginia Researchers Publish New Study on Tropomyosin Proteoforms Showcasing Quantum-Si’s Next-Gen Protein Sequencer™ Platinum®

QSI 11.07.2024

Full Press ReleaseSEC FilingsOur QSI Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Microproteins and the Dark Proteome: Tiny Molecules with Big Potential
  • 01.22.2025 - Quantum-Si’s Innovative Protein Barcoding Enhances Next-Gen Screening for mRNA Therapeutics
  • 01.20.2025 - Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK

Recent Filings

    Published Preprint Demonstrates Platinum’s Capability to Discriminate Peptide Variants with Single Amino Acid Resolution

    BRANFORD, Conn.--(BUSINESS WIRE)--Nov. 7, 2024--Quantum-Si Incorporated(Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced a newly released preprint publication on BioRxiv, from Dr.Gloria Sheynkmanat theUniversity of Virginia School of Medicine. In the publication, Sheynkman and team demonstrate the application of Quantum-Si’s PlatinumTM single-molecule benchtop sequencer to distinguish proteoform-informative peptides within the human tropomyosin (TPM) gene family. This study highlights Platinum’s ability to achieve single amino acid resolution, revealing variations that differentiate crucial tissue-specific and modified protein forms.

    Titled"Protein Sequencing with Single Amino Acid Resolution Discerns Peptides that Discriminate Tropomyosin Proteoforms,"the preprint describes how the Platinum sequencer differentiates TPM1 and TPM2 paralogous peptides that vary by only a single amino acid. It also explores the instrument’s ability to resolve phosphotyrosine modifications and TPM2 splice variants, underscoring the potential for NGPS to advance multi-omics research by providing insight into proteoform presence, structure, and function. (https://www.quantum-si.com/preprint-110724/)

    “Our data highlight Platinum’s ability to accurately distinguish all major types of proteoform variation within the TPM gene family,” saidDr. Sheynkman. “This provides a more precise window into complex protein families, and this capability to precisely sequence and distinguish peptide variations paves the way for numerous applications in disease research and biomarker discovery.”

    The study further explores Platinum’s capability to differentiate highly similar peptides that may define isoforms with distinct functions. Platinum’s single amino acid resolution enables it to detect sequences with molecular weights that challenge traditional mass spectrometry (MS) techniques, making it a complementary tool for MS and an asset for proteomics researchers focused on nuanced peptide differences.

    “This collaboration withDr. Sheynkmanand her team at theUniversity of Virginiahighlights Platinum’s role in pushing the boundaries of proteomics,” saidJeff Hawkins, CEO ofQuantum-Si. “Seeing our instrument empower researchers to unravel proteomic complexity at the single-molecule level is exciting. This work not only establishes our technology's unique capabilities but also exemplifies the impactful discoveries it can make possible for researchers.”

    For more information on Quantum-Si’s technology and research applications, please visitThe Protein Sequencing CompanyTM |Quantum-Si

    AboutQuantum-Si Incorporated

    Quantum-Si, The Protein Sequencing CompanyTM, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein SequencingTM that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more atquantum-si.comor follow us onLinkedInorX.

    View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241107799485/en/

    InvestorDoug Farrell, VP, Investor Relationsir@quantum-si.comMediaKatherine Atkinson, SVP, Commercial Marketingmedia@quantum-si.com

    Source:Quantum-Si Incorporated

    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com